Workup of Suspected Chest Metastases on 18 F-FDG-PET/CT in Head and Neck Cancer: Worth the Wait?

Christopher J. Leto, Daniel Sharbel, Chien Wei Wang, Tyler M. Bone, Robert M. Liebman, James Kenneth Byrd, Michael W Groves

Research output: Contribution to journalArticle

Abstract

The objective of our study is to assess the impact of equivocal or positive positron emission tomography combined with low-dose noncontrast computed tomography (PET/CT) findings in the chest on treatment for head and neck cancer (HNC). We reviewed charts of patients presented at Augusta University’s Head and Neck Tumor Board (AUTB) between 2013 and 2016 with the following exclusion criteria: <18 years, Veterans Affairs patients, those with incomplete data, and those without a history of head and neck squamous cell carcinoma. The lung/thorax sections of the radiologists’ PET/CT reports were graded as “Positive, Equivocal, or Negative” for chest metastases. Patients who underwent workup for suspected chest metastases were assessed for treatment delays, changes in treatment plans, and complications. In addition, we evaluated the time between AUTB presentation and peri-treatment PET/CT to primary treatment initiation were calculated between groups. There was a total of 363 patients with PET/CT prior to treatment, the read was “Negative” in 71.3% (n = 259), “Equivocal” in 20.9% (n = 76), and “Positive” in 5.8% (n = 21). Of 272 patients with complete treatment data, 22 underwent workup for suspected chest metastases. Mean time from PET/CT to treatment initiation was 27.5 days without workup and 64.9 days with workup (P <.0001), and from AUTB presentation was 29.1 days without workup and 62.5 days with workup (P <.0001). Five (19.2%) patients experienced a complication from workup. Twenty (76.9%) patients had no changes in their treatment plan after workup. In conclusion, our results for potential chest metastases on PET/CT in patients with HNC are often not clear-cut. Workup of suspected chest metastasis based on PET/CT findings significantly delays primary treatment initiation and may cause serious complications.

Original languageEnglish (US)
Pages (from-to)158-164
Number of pages7
JournalEar, Nose and Throat Journal
Volume98
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Head and Neck Neoplasms
Thorax
Neoplasm Metastasis
Therapeutics
Neck
Head
Neoplasms
Veterans
Positron-Emission Tomography
Tomography
Lung

Keywords

  • PET/CT
  • chest metastasis
  • head and neck cancer
  • preoperative imaging
  • treatment delay

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Workup of Suspected Chest Metastases on 18 F-FDG-PET/CT in Head and Neck Cancer : Worth the Wait? / Leto, Christopher J.; Sharbel, Daniel; Wang, Chien Wei; Bone, Tyler M.; Liebman, Robert M.; Byrd, James Kenneth; Groves, Michael W.

In: Ear, Nose and Throat Journal, Vol. 98, No. 3, 01.03.2019, p. 158-164.

Research output: Contribution to journalArticle

Leto, Christopher J. ; Sharbel, Daniel ; Wang, Chien Wei ; Bone, Tyler M. ; Liebman, Robert M. ; Byrd, James Kenneth ; Groves, Michael W. / Workup of Suspected Chest Metastases on 18 F-FDG-PET/CT in Head and Neck Cancer : Worth the Wait?. In: Ear, Nose and Throat Journal. 2019 ; Vol. 98, No. 3. pp. 158-164.
@article{10d88bc52d0149bfabc5cd7ac0d1c427,
title = "Workup of Suspected Chest Metastases on 18 F-FDG-PET/CT in Head and Neck Cancer: Worth the Wait?",
abstract = "The objective of our study is to assess the impact of equivocal or positive positron emission tomography combined with low-dose noncontrast computed tomography (PET/CT) findings in the chest on treatment for head and neck cancer (HNC). We reviewed charts of patients presented at Augusta University’s Head and Neck Tumor Board (AUTB) between 2013 and 2016 with the following exclusion criteria: <18 years, Veterans Affairs patients, those with incomplete data, and those without a history of head and neck squamous cell carcinoma. The lung/thorax sections of the radiologists’ PET/CT reports were graded as “Positive, Equivocal, or Negative” for chest metastases. Patients who underwent workup for suspected chest metastases were assessed for treatment delays, changes in treatment plans, and complications. In addition, we evaluated the time between AUTB presentation and peri-treatment PET/CT to primary treatment initiation were calculated between groups. There was a total of 363 patients with PET/CT prior to treatment, the read was “Negative” in 71.3{\%} (n = 259), “Equivocal” in 20.9{\%} (n = 76), and “Positive” in 5.8{\%} (n = 21). Of 272 patients with complete treatment data, 22 underwent workup for suspected chest metastases. Mean time from PET/CT to treatment initiation was 27.5 days without workup and 64.9 days with workup (P <.0001), and from AUTB presentation was 29.1 days without workup and 62.5 days with workup (P <.0001). Five (19.2{\%}) patients experienced a complication from workup. Twenty (76.9{\%}) patients had no changes in their treatment plan after workup. In conclusion, our results for potential chest metastases on PET/CT in patients with HNC are often not clear-cut. Workup of suspected chest metastasis based on PET/CT findings significantly delays primary treatment initiation and may cause serious complications.",
keywords = "PET/CT, chest metastasis, head and neck cancer, preoperative imaging, treatment delay",
author = "Leto, {Christopher J.} and Daniel Sharbel and Wang, {Chien Wei} and Bone, {Tyler M.} and Liebman, {Robert M.} and Byrd, {James Kenneth} and Groves, {Michael W}",
year = "2019",
month = "3",
day = "1",
doi = "10.1177/0145561319828315",
language = "English (US)",
volume = "98",
pages = "158--164",
journal = "Ear, Nose and Throat Journal",
issn = "0145-5613",
publisher = "Medquest Communications LLC",
number = "3",

}

TY - JOUR

T1 - Workup of Suspected Chest Metastases on 18 F-FDG-PET/CT in Head and Neck Cancer

T2 - Worth the Wait?

AU - Leto, Christopher J.

AU - Sharbel, Daniel

AU - Wang, Chien Wei

AU - Bone, Tyler M.

AU - Liebman, Robert M.

AU - Byrd, James Kenneth

AU - Groves, Michael W

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The objective of our study is to assess the impact of equivocal or positive positron emission tomography combined with low-dose noncontrast computed tomography (PET/CT) findings in the chest on treatment for head and neck cancer (HNC). We reviewed charts of patients presented at Augusta University’s Head and Neck Tumor Board (AUTB) between 2013 and 2016 with the following exclusion criteria: <18 years, Veterans Affairs patients, those with incomplete data, and those without a history of head and neck squamous cell carcinoma. The lung/thorax sections of the radiologists’ PET/CT reports were graded as “Positive, Equivocal, or Negative” for chest metastases. Patients who underwent workup for suspected chest metastases were assessed for treatment delays, changes in treatment plans, and complications. In addition, we evaluated the time between AUTB presentation and peri-treatment PET/CT to primary treatment initiation were calculated between groups. There was a total of 363 patients with PET/CT prior to treatment, the read was “Negative” in 71.3% (n = 259), “Equivocal” in 20.9% (n = 76), and “Positive” in 5.8% (n = 21). Of 272 patients with complete treatment data, 22 underwent workup for suspected chest metastases. Mean time from PET/CT to treatment initiation was 27.5 days without workup and 64.9 days with workup (P <.0001), and from AUTB presentation was 29.1 days without workup and 62.5 days with workup (P <.0001). Five (19.2%) patients experienced a complication from workup. Twenty (76.9%) patients had no changes in their treatment plan after workup. In conclusion, our results for potential chest metastases on PET/CT in patients with HNC are often not clear-cut. Workup of suspected chest metastasis based on PET/CT findings significantly delays primary treatment initiation and may cause serious complications.

AB - The objective of our study is to assess the impact of equivocal or positive positron emission tomography combined with low-dose noncontrast computed tomography (PET/CT) findings in the chest on treatment for head and neck cancer (HNC). We reviewed charts of patients presented at Augusta University’s Head and Neck Tumor Board (AUTB) between 2013 and 2016 with the following exclusion criteria: <18 years, Veterans Affairs patients, those with incomplete data, and those without a history of head and neck squamous cell carcinoma. The lung/thorax sections of the radiologists’ PET/CT reports were graded as “Positive, Equivocal, or Negative” for chest metastases. Patients who underwent workup for suspected chest metastases were assessed for treatment delays, changes in treatment plans, and complications. In addition, we evaluated the time between AUTB presentation and peri-treatment PET/CT to primary treatment initiation were calculated between groups. There was a total of 363 patients with PET/CT prior to treatment, the read was “Negative” in 71.3% (n = 259), “Equivocal” in 20.9% (n = 76), and “Positive” in 5.8% (n = 21). Of 272 patients with complete treatment data, 22 underwent workup for suspected chest metastases. Mean time from PET/CT to treatment initiation was 27.5 days without workup and 64.9 days with workup (P <.0001), and from AUTB presentation was 29.1 days without workup and 62.5 days with workup (P <.0001). Five (19.2%) patients experienced a complication from workup. Twenty (76.9%) patients had no changes in their treatment plan after workup. In conclusion, our results for potential chest metastases on PET/CT in patients with HNC are often not clear-cut. Workup of suspected chest metastasis based on PET/CT findings significantly delays primary treatment initiation and may cause serious complications.

KW - PET/CT

KW - chest metastasis

KW - head and neck cancer

KW - preoperative imaging

KW - treatment delay

UR - http://www.scopus.com/inward/record.url?scp=85061576237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061576237&partnerID=8YFLogxK

U2 - 10.1177/0145561319828315

DO - 10.1177/0145561319828315

M3 - Article

C2 - 30938238

AN - SCOPUS:85061576237

VL - 98

SP - 158

EP - 164

JO - Ear, Nose and Throat Journal

JF - Ear, Nose and Throat Journal

SN - 0145-5613

IS - 3

ER -